Published in Exp Ther Med on May 26, 2016
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol (2015) 2.09
Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol (2000) 1.56
Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res (2015) 1.08
Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer (2011) 1.08
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Lett (2014) 1.06
Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature. Leuk Res (2007) 0.99
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. J Cancer (2016) 0.93
Moving disease biology from the lab to the clinic. Cancer (2003) 0.93
Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells. Leuk Res (2015) 0.92
The effect of thalidomide on ethanol-induced gastric mucosal damage in mice: involvement of inflammatory cytokines and nitric oxide. Chem Biol Interact (2014) 0.83
Overexpression of survivin and caspase 3 in oral carcinogenesis. Appl Immunohistochem Mol Morphol (2014) 0.83
LMP-1 induces survivin expression to inhibit cell apoptosis through the NF-κB and PI3K/Akt signaling pathways in nasal NK/T-cell lymphoma. Oncol Rep (2015) 0.82
Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. Exp Hematol (2014) 0.82
Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Lett (2015) 0.82
Evolving diagnostic criteria for multiple myeloma. Hematology Am Soc Hematol Educ Program (2015) 0.82
The Declaration of Helsinki, 50 years later. JAMA (2013) 0.81
Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant (2014) 0.80
Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol (2015) 0.80
Elevated survivin mediated multidrug resistance and reduced apoptosis in breast cancer stem cells. J BUON (2015) 0.80
MGMT inhibition suppresses survivin expression in pancreatic cancer. Pancreas (2015) 0.78
In vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs. Int Immunopharmacol (2014) 0.78
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biol Blood Marrow Transplant (2013) 0.78
Stem cell markers OCT4 and nestin in laryngeal squamous cell carcinoma and their relation to survivin expression. Pathol Res Pract (2014) 0.78
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Leuk Res (2014) 0.78
The diagnostic value of survivin in malignant pleural effusion: a meta-analysis. Clin Chim Acta (2015) 0.78
Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev (2016) 0.78
PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice. Immunobiology (2014) 0.77
Risk Stratification in Multiple Myeloma. Curr Hematol Malig Rep (2016) 0.77
[Clinical Features of 46 Multiple Myeloma Patients with Different Renal Pathology]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2016) 0.77
Survivin expression in canine lymphomas in relation with proliferative markers. Pol J Vet Sci (2015) 0.77
[Clinical observation of DECP combination chemotherapy for relapsing and refractory multiple myeloma patients with extramedullary plasmacytomas]. Zhonghua Yi Xue Za Zhi (2014) 0.77
Induction of apoptosis in multiple myeloma cells by a statin-thalidomide combination can be enhanced by p38 MAPK inhibition. Leuk Res (2013) 0.77
Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases. Mol Clin Oncol (2015) 0.76
Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro. Thromb Res (2015) 0.76
Effect on apoptosis and cell cycle of recombinant double negative dominant mutation Survivin (T34/117A) in breast cancer cell B-Cap-37. Biomed Pharmacother (2013) 0.76
Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends. BMJ Open (2016) 0.76
[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients]. Zhonghua Xue Ye Xue Za Zhi (2008) 0.76
[Effects of fludarabine on apoptosis and gene expression profile in multiple myeloma cells]. Zhonghua Xue Ye Xue Za Zhi (2010) 0.76
Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging (2016) 0.76